Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water

Movement Disorders Clinical Trial

— ValiDLW  

Official title:

Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05736302
• Other study ID #: 21.061
• Secondary ID: R01CA215318
• Status: Recruiting
• Start date: March 14, 2023
• Est. completion date: March 31, 2025

Study information

• Verified date: May 2023
• Source: University of Wisconsin, Milwaukee
• Contact: Katharine O'Connell Valuch
• Phone: 414-229-4115
• Email: oconnell[@]uwm.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.

Description:

Current algorithms for examining accelerometer data were developed primarily using data from individuals without movement limitations or impairments. As such, the current available analytic algorithms are inadequate for use with individuals with limitations and impairments to estimate total daily energy expenditure (TDEE). The creation of a new algorithm that can accurately assess TDEE in individuals with movement limitations will be beneficial for future research examining physical activity interventions targeted to these individuals. This study will serve to validate a new algorithm that was developed specifically to analyze accelerometer data for individuals with movement limitations, and gauge the accuracy of the new algorithm's ability to accurately assess TDEE against one of the gold standards of TDEE measurement, the doubly labelled water technique.

Approximately 125 adults, 50 from Colorado, and 75 from Wisconsin, will participate in this study. Participants will complete three study visits. During the first visit, physical function will be assessed during a series of tests, and a dual-energy X-ray absorptiometry (DXA) scan will be performed to obtain information on body composition. During the second visit, the participant will complete a resting metabolic rate (RMR) examination, will consume a dose of doubly labeled water, and will provide urine and saliva samples. At the end of the second visit, participants will be given a set of accelerometers to wear for 8-10 days, and will be asked to complete a wear log for documentation. After 8-10 days have passed, during the final visit, participants will provide additional urine samples and return the accelerometers.

The hypothesis being tested is that physical function-clustered specific machine-learned accelerometer algorithms will produce more accurate and precise estimations of TDEE during free-living compared with healthy population derived accelerometer algorithms applied to diverse populations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 125
• Est. completion date: March 31, 2025
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• must be 18+ years of age

• be able to ambulate on own, unassisted, on a regular basis

• speak and read English

• must have access to a working smart phone and a computer with internet access

Exclusion Criteria:

• wheelchair reliant

• assistive walking device reliant (cannot walk for at least 50 feet without an assistive device)

• diagnosed uncontrolled hypertension (above 160/100 mgHg)

• diagnosed cognitive impairment or inability to follow study procedures such as Alzheimer's disease or dementia

• cannot take metabolic altering medications

• cannot be pregnant

• cannot be breastfeeding

• cannot use supplemental oxygen

• cannot completed required study activities for any reason

• cannot have a resting heart rate > 100 bpm or a resting blood pressure > 160 mgHg during Visit 1

• cannot weigh more than 450 lbs

Related Conditions & MeSH terms

• Energy Metabolism
• Movement Disorders

Intervention

Other:
• Doubly-Labeled Water
All eligible participants will receive a dose of doubly-labeled water.

Locations

Country	Name	City	State
United States	University of Wisconsin-Milwaukee	Milwaukee	Wisconsin

Sponsors (4)

Lead Sponsor	Collaborator
University of Wisconsin, Milwaukee	National Cancer Institute (NCI), University of Colorado, Denver, University of Massachusetts, Amherst

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of accelerometer derived estimations of total daily energy expenditure (TDEE, kcals/day).	Accelerometer estimations will be derived by different algorithms available in the literature, as well as from a newly developed algorithm that distinguishes between those with and without movement limitations. Accelerometer estimations of TDEE will be compared to those values obtained by the criterion doubly-labeled water technique.	8-10 days monitoring
Primary	Precision of accelerometer derived estimations of total daily energy expenditure (TDEE, kcals/day).	Accelerometer estimations will be derived by different algorithms available in the literature, as well as from a newly developed algorithm that distinguishes between those with and without movement limitations. Accelerometer estimations of TDEE will be compared to those values obtained by the criterion doubly-labeled water technique.	8-10 days monitoring
Primary	Total Daily Energy Expenditure (TDEE) (via DLW)	Total daily energy expenditure (TDEE) over the 8-10 day period as measured by the difference in presence of isotopes in the samples at Visit 3. The 18-O and deuterium exit the body through slightly different mechanisms, so when we examine the difference in levels present at the end of the 8-10 day period between Visit 2 and Visit 3, we can estimate carbon dioxide (CO2) production and hence, energy expenditure. The samples taken at Visit 2 provide the baseline information required to analyze the samples taken at Visit 3 and calculate TDEE.	pre-dose; 4 hours and 5 hours post-dose, and 8-10 days post-dose
Secondary	Resting Metabolic Rate (kcals/day)	Basal metabolic rate as determined by fasting RMR test, conducted via Parvomedics TrueOne 2400 Metabolic system. Results include the approximate number of calories an individual would expend if they spent the day in a resting state.	pre-dose
Secondary	Fat free body mass (g)	Dual x-ray absorptiometry (DEXA) measurement of body composition, conducted via a Hologic Horizon W system. Results include the amount of fat, bone mineral density, and fat free mass, measured in grams. The fat free mass measurement is used to calculate the dose of doubly labeled water for the participant.	7-14 days before dose
Secondary	Modified Physical Performance Test (MPPT)	The modified physical performance test consists of 9 subtests that are used to assess level of physical function. Total scores range from 0-36. Not frail = 32-36, Mildly frail = 25-31, Moderately frail = 17-24, and less than 17= low function.	7-14 days before dose
Secondary	Maximum hand grip strength	Hand grip is measured via a hand grip dynamometer manufactured by Lafayette Instruments, and is equivalent to the Jamar hand grip dynamometer. The results are measured in lbs, and can range from 0 lbs to 250 lbs. Cut offs for normal hand grip strength vary significantly dependent upon age, sex, country of origin, and BMI. Lower hand grip strength is associated with lower physical function.	7-14 days before dose
Secondary	Gait speed	Gait speed is measured via the 10 meter walk test, with three repetitions of the test at a normal walking speed, and three repetitions of the test at a fast walking speed. A number of different published cut-offs exist for this test, but a cut-off of 1.0 m/sec is recognized as being an indicator of lower physical function. Individuals who ambulate slower than 1.0 m/sec are at risk of not being able to function in the community.	7-14 days before dose
Secondary	Temporospatial gait analysis	Analysis of gait to determine whether anomalies are present via the GAITrite system. Over 50 variables are taken into account in the analysis. These results are compared to standardized norms (sex and age based), and elements of the analysis that are abnormal compared to those norms are indicated in the system output.	7-14 days before dose